Zydus Pharmaceuticals (USA) Inc. is recalling 7,248 bottles of Oxybutynin Chloride Extended-Release Tablets (10 mg), used to treat overactive bladder, because the tablets failed dissolution testing. This means the medication may not dissolve at the correct rate in the body, which can impact how effectively the drug works. This recall affects both 100-count and 500-count bottles distributed nationwide, and no injuries or incidents have been reported to date.
If the medication fails to dissolve as specified, the patient may not receive the intended dose of the drug, potentially leading to a return of overactive bladder symptoms. There is also a risk that the drug could release too quickly or too slowly, impacting the safety and efficacy of the treatment.
You have 2 options:
Bottles of 100 and 500 tablets; Rx Only.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.